# Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients

## TL;DR

This study explores how PD-1 and PD-L1 expression affects treatment outcomes in patients with newly diagnosed acute myeloid leukemia.

## Contribution

The study identifies a link between PD-1/PD-L1 expression levels and clinical outcomes in newly diagnosed AML patients.

## Key findings

- Non-responders showed significantly higher PD-1 expression in CD3+ and CD4+ T cells.
- AML patients had higher PD-1 expression in T lymphocytes in bone marrow compared to peripheral blood.
- PD-1/PD-L1 expression was associated with clinical traits in newly diagnosed AML patients.

## Abstract

High expression of immune checkpoint markers may leukemic cells to evade the immune system in AML. This study aimed to investigate the relationship between PD-1/PD-L1 expression and treatment outcomes in AML patients.. The study included 21 patients and 18 healthy volunteers. Non-responders exhibited significantly higher PD-1 expression (MFI) in CD3+ and CD4+ T cells. At the time of diagnosis, bone marrow samples from patients exhibited a significantly higher proportion of PD-1 expression in CD3+, CD4+, and CD8+ T lymphocytes than peripheral blood samples. The results revealed an association between PD-1/PD-L1 expression and clinical traits in newly diagnosed AML patients.